Page last updated: 2024-11-02

pioglitazone and Substance Withdrawal Syndrome

pioglitazone has been researched along with Substance Withdrawal Syndrome in 9 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.

Research Excerpts

ExcerptRelevanceReference
"We showed that activation of PPARγ receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking."7.77Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. ( Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S, 2011)
"We showed that activation of PPARγ receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking."3.77Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. ( Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S, 2011)
"Naloxone was administrated 2 h after the morphine last dose, and withdrawal symptoms were recorded for 45 min."1.40Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats. ( Azarfardian, A; Charkhpour, M; Ghasami, S; Ghavimi, H; Hassanzadeh, K; Maleki-Dizaji, N; Zolali, E, 2014)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Domi, E1
Caputi, FF1
Romualdi, P1
Domi, A1
Scuppa, G2
Candeletti, S1
Atkins, A1
Heilig, M3
Demopulos, G3
Gaitanaris, G3
Ciccocioppo, R3
Ubaldi, M1
Pariente, A1
Mansiaux, Y1
Jarné, A1
Salvo, F1
Pageot, C1
Bezin, J1
Smith, A1
Bégaud, B1
Schroeder, JR1
Phillips, KA1
Epstein, DH1
Jobes, ML1
Furnari, MA1
Kennedy, AP1
Preston, KL1
Ghavimi, H2
Azarfardian, A2
Maleki-Dizaji, N2
Hassanzadeh, K2
Ghanbarzadeh, S1
Charkhpour, M2
Ghasami, S1
Zolali, E1
Tripathy, D1
Schwenke, DC1
Banerji, M1
Bray, GA1
Buchanan, TA1
Clement, SC1
Henry, RR1
Kitabchi, AE1
Mudaliar, S1
Ratner, RE1
Stentz, FB1
Musi, N1
Reaven, PD1
DeFronzo, RA1
de Guglielmo, G1
Kallupi, M2
Stopponi, S1
Somaini, L1
Cippitelli, A1
Cannella, N1
Braconi, S1
Ruggeri, B1
Massi, M1
Javadi, S1
Ejtemaeimehr, S1
Keyvanfar, HR1
Moghaddas, P1
Aminian, A1
Rajabzadeh, A1
Mani, AR1
Dehpour, AR1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pioglitazone as an Aid During Buprenorphine Taper[NCT01517165]Phase 124 participants (Actual)Interventional2012-01-04Terminated
Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961]Phase 3602 participants (Actual)Interventional2004-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Fasting Plasma Glucose of 2.4 Years

Fasting Plasma Glucose (NCT00220961)
Timeframe: Baseline versus 2.4 years

Interventionmg/dl (Mean)
Placebo-4.0
Pioglitazone-10.7

Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)

Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years

Interventionmatsuda index (Mean)
Placebo0.7
Pioglitazone3.6

Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test

Insulin secretion (NCT00220961)
Timeframe: Baseline versus 2.4 years

Interventionnmol (Mean)
Placebo35
Pioglitazone25

Change in Atherosclerosis

carotid intima thickness (NCT00220961)
Timeframe: Baseline versus 2.4 years

Interventionpercentage of intima (Mean)
Placebo1.7
Pioglitazone3.2

Prevention of Type 2 Diabetes

Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years

Interventionpercentage of participants (Number)
Placebo16.1
Pioglitazone5.0

Trials

1 trial available for pioglitazone and Substance Withdrawal Syndrome

ArticleYear
Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Psychopharmacology, 2018, Volume: 235, Issue:10

    Topics: Adult; Analgesics, Opioid; Buprenorphine; Cytokines; Double-Blind Method; Female; Humans; Male; Midd

2018

Other Studies

8 other studies available for pioglitazone and Substance Withdrawal Syndrome

ArticleYear
Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2019, 12-04, Volume: 39, Issue:49

    Topics: Affect; Amygdala; Anilides; Animals; Anxiety; Behavior, Animal; gamma-Aminobutyric Acid; Hippocampus

2019
Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:12

    Topics: Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Substance Withdrawal

2017
Acute administration of pioglitazone attenuates morphine withdrawal syndrome in rat: a novel role of pioglitazone.
    Drug research, 2015, Volume: 65, Issue:3

    Topics: Analgesics, Opioid; Anilides; Animals; Male; Morphine; Morphine Dependence; Naloxone; Pioglitazone;

2015
Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2014, Volume: 387, Issue:9

    Topics: Analgesics, Opioid; Anilides; Animals; Behavior, Animal; Drug Tolerance; Male; Morphine; Motor Activ

2014
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
    The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:5

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Insulin; I

2016
Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents.
    Psychopharmacology, 2017, Volume: 234, Issue:2

    Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Conditioning, Operant; Heroin; Male; Mice; Morphin

2017
Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.
    Biological psychiatry, 2011, Apr-01, Volume: 69, Issue:7

    Topics: Adrenergic alpha-2 Receptor Antagonists; Alcohol Drinking; Alcohols; Analysis of Variance; Anilides;

2011
Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway.
    Brain research, 2013, May-13, Volume: 1510

    Topics: Animals; Cell Line, Tumor; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Enzyme Inhibitors; Gliobl

2013